SYSTEM AND METHOD FOR THERAPEUTIC MANAGEMENT OF COUGH
One embodiment is directed to a method for controllably managing unproductive cough in a patient having a tissue structure that has been genetically modified to have light sensitive protein, comprising: providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source; and operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.
1 . A method for controllably managing unproductive cough in a patient having a tissue structure that has been genetically modified to have light sensitive protein, comprising:
a. providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source; and
b. operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.
2 . The method of claim 1 , wherein the targeted tissue structure is a branch of the Vagus nerve.
3 . The method of claim 1 , further comprising disposing the applicator to illuminate the target tissue structure, the applicator being comprised of at least a light delivery element and a sensor, wherein the sensor is configured to:
a. produce an electrical signal representative of the state of the target tissue or its environment; and
b. deliver the signal to the controller, wherein the controller is further configured to interpret the signal from the sensor and adjust at least one light source output parameter such that the signal is maintained within a desired range, wherein the light source output parameter may be chosen from the group containing of; current, voltage, optical power, irradiance, pulse duration, pulse interval time, pulse repetition frequency, and duty cycle.
4 . The method of claim 3 , wherein the sensor is selected from the group consisting of: an optical sensor, a temperature sensor, a chemical sensor, and an electrical sensor.
5 . The method of claim 1 , wherein the controller is further configured to drive the light source in a pulsatile fashion.
6 . The method of claim 5 , wherein the current pulses are of a duration within the range of 1 millisecond to 100 seconds.
7 . The method of claim 5 , wherein the duty cycle of the current pulses is within the range of 99% to 0.1%.
8 . The method of claim 1 , wherein the controller is responsive to a patient input.
9 . The method of claim 8 , wherein the patient input triggers the delivery of current.
10 . The method of claim 5 , wherein the current controller is further configured to control one or more variables selected from the group consisting of; the current amplitude, the pulse duration, the duty cycle, and the overall energy delivered.
11 . The method of claim 1 , wherein the light delivery element is placed about at least 60% of circumference of a nerve or nerve bundle.
12 . The method of claim 1 , wherein the light sensitive protein is an opsin protein.
13 . The method of claim 12 , wherein the opsin protein is selected from the group consisting of: a depolarizing opsin, a hyperpolarizing opsin, a stimulatory opsin, an inhibitory opsin, a chimeric opsin, and a step-function opsin.
14 . The method of claim 12 , wherein the opsin protein is selected from the group consisting of: NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, SwiChR, Mac, Mac 3.0, Arch, ArchT, iChR, ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, ChR2-SFO, ChloC, and iC1C2.
15 . The method of claim 1 , wherein the light sensitive protein is delivered to the target tissue using a virus.
16 . The method of claim 15 , wherein the virus is selected from the group consisting of: AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, lentivirus, and HSV.
17 . The method of claim 15 , wherein the virus contains a polynucleotide that encodes for the opsin protein.
18 . The method of claim 17 , wherein the polynucleotide encodes for a transcription promoter.
19 . The method of claim 18 , wherein the transcription promoter is selected from the group consisting of: hSyn, CMV, Hb9Hb, Thy1, and Ef1a.